Yi Yang

Dr. Yi Yang


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2024 in Frontiers in Psychology
Verified
Journal Article
Open access
PDF file
ZNZihan Ni
Zihan Ni
XZXiuyuan Zhu
Xiuyuan Zhu
KTKan Tian
Kan Tian
QCQing Chen
Qing Chen
YYYi Yang
Yi Yang
SXShiyu Xie
Shiyu Xie
Objective: To explore the mediating roles of activities of daily living (ADL) and economic burden of diseases in the relationship between chronic diseases and depressive symptoms of older adults.Methods: The data were sourced from China Health and Retirement Longitudinal Study (CHARLS). The number of chronic diseases, ADL, out-of-pocket medical expenses and the Center for Epidemiological Studies Depression Scale (CES-D) were selected as measuring indexes. Mediation analysis was conducted to explore the potential mediating roles of ADL and economic burden of diseases in the association between chronic diseases and depressive symptoms.Results: The number of chronic diseases, ADL, economic burden of diseases and depressive symptoms of older adults were significantly correlated with each other. ADL and economic burden of diseases individually mediated the relationship between the number of chronic diseases and depressive symptoms, accounting for 31.460% and 5.471% of the total effect, respectively. Additionally, ADL and economic burden of diseases demonstrated a chain mediating effect in this relationship, contributing to 0.759% of the total effect.Conclusion: The chain-mediated model effectively elucidated the mediating roles of ADL and economic burden of diseases in the association between chronic diseases and depressive symptoms among older adults. The study underscores the need for policymakers to focus attentively on the mental health of older adults with chronic diseases. Enhancing the capacity for ADL and strengthening social security to mitigate the economic burden of diseases are recommended strategies to alleviate depressive symptoms in older adults.

1 December 2019 in Global Health Journal
Verified
Journal Article
Open access
YYYi Yang
Yi Yang
KTKan Tian
Kan Tian
GBGengliang Bai
Gengliang Bai
XZXiangyuan Zhu
Xiangyuan Zhu
YYYong Yang
Yong Yang
LSLizheng Shi
Lizheng Shi

22 June 2023 in Integrative Medicine Research
Verified
Journal Article
Open access
YTYue Teng
Yue Teng
YWYan Wei
Yan Wei
YCYingyao Chen
Yingyao Chen
JYJuntao Yan
Juntao Yan
SLShimeng Liu
Shimeng Liu
YYYi Yang
Yi Yang
Traditional Chinese Medicine (TCM), integrating patient preferences into decision-making process, has been widely used in the multimodality therapy of lung cancer. This study aimed to estimate patient preferences for treatment and shared decision-making (SDM) modes concerning inpatient TCM treatment of lung cancer in Shanghai in order to provide a basis for clinical decision-making process on TCM therapy for lung cancer. This study was conducted among patients (n = 347) from nine tertiary hospitals in Shanghai by discrete-choice experiment (DCE) survey and Shared Decision-Making Questionnaire-patient version (SDM-Q-9) survey. The DCE was developed with the inclusion of the most relevant attributes at appropriate levels for the TCM treatment of lung cancer. The empirical data analyses of patients were performed using mixed logit models. Additionally, subgroup analysis was conducted. In total, 347 respondents completed the questionnaire. All attributes’ coefficients were statistically significant for patients’ preferences. Patients showed strong preferences for increasing disease control rate, relieving nausea and vomiting, reducing the risk of side effects, and were concerned about monthly out-of-pocket costs. Subgroup analysis indicated that patients with a lower SDM-Q-9 score and those who were satisfied with medical services emphasized more importance of higher disease control rate. Furthermore, most of the patients (90.20%) self-reported a high willingness to use SDM during the decision-making process. In Shanghai, patients mainly preferred SDM and considered disease control rate as the most essential attribute in the TCM treatment of lung cancer. The study findings could underscore the importance of considering patients’ preferences and promote SDM.

1 January 2015 in Oncology Letters
Verified
Journal Article
Open access
PDF file
RZRu Zhou
Ru Zhou
YCYantao Cai
Yantao Cai
YYYi Yang
Yi Yang
JXJianbin Xiang
Jianbin Xiang
ZCZongyou Chen
Zongyou Chen
Hepatoid adenocarcinoma is a rare tumor, associated with an extremely poor prognosis. In the present report, a 72‑year‑old female presented to Huashan Hospital (Shanghai, China) with upper abdominal discomfort and, following endoscopy, an ulcerated lesion was observed in the stomach. A computed tomography scan revealed a mass in the antrum of the stomach and the α‑fetoprotein level was normal. Sections of the mass exhibited malignant cells arranged in a solid to trabecular pattern; the cells were polygonal shaped with well‑defined cytoplasmic borders. Immunohistochemical analysis was performed and the cells were positive for Hep1, CK, CK8, CK18 and P53. The histological features together with the immunohistochemical findings were diagnostic of a hepatoid adenocarcinoma of the stomach. Immunohistochemical studies may aid in the identification of the characteristic features and prevent the misdiagnosis of this tumor.

16 May 2024 in Cancer Medicine
Verified
Journal Article
Open access
DLDai Lian
Dai Lian
YGYuling Gan
Yuling Gan
DXDunming Xiao
Dunming Xiao
DXDennis Xuan
Dennis Xuan
YCYingyao Chen
Yingyao Chen
YYYi Yang
Yi Yang
Background: Toripalimab, combined with gemcitabine and cisplatin, has been approved as the first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma (RM‐NPC), representing a significant milestone as the first FDA‐approved innovative therapy for this condition. Despite this achievement, there's a lack of data on the cost‐effectiveness of toripalimab for RM‐NPC patients in the American context.Methods: To assess the cost‐effectiveness of toripalimab plus chemotherapy versus chemotherapy alone, a 3‐state partitioned survival model was constructed. The study involved participants with characteristics matching those in the JUPITER‐02 trial. Cost and utility inputs were collected from literature. Main outcomes measured were quality‐adjusted life year (QALY), and incremental cost‐effectiveness ratio (ICER). Univariate and probabilistic sensitivity analyses, subgroup analyses, and scenario analyses were conducted to verify the robustness of results.Results: The study found that the toripalimab regimen resulted in 4.390 QALYs at a cost of $361,813, while the chemotherapy‐only regimen yielded 1.685 QALYs at a cost of $161,632. This translates to an ICER of $74,004/QALY, below the willingness‐to‐pay threshold of $150,000/QALY. Sensitivity analyses indicated that utility values, discount rate, and the price of toripalimab significantly impact INMB. With an 87.10% probability of being cost‐effective at a $150,000/QALY threshold, the probabilistic sensitivity analysis supports toripalimab plus chemotherapy as a viable option. Scenario analysis showed that toripalimab remains cost‐effective unless its price increases by 125%. Additionally, a simulated 15‐year study period increases the ICER to $88,026/QALY. Subgroup analysis revealed ICERs of $76,538/QALY for PD‐L1 positive and $70,158/QALY for PD‐L1 negative groups.Conclusions: Toripalimab in combination with chemotherapy is likely to be a cost‐effective alternative to standard chemotherapy for American patients with RM‐NPC. This evidence can guide clinical and reimbursement decision‐making in treating RM‐NPC patients.

15 February 2024 in Advances in Therapy
Verified
Journal Article
Closed access
PDF file
FLFuming Li
Fuming Li
YCYingyao Chen
Yingyao Chen
DXDunming Xiao
Dunming Xiao
SJShan Jiang
Shan Jiang
YYYi Yang
Yi Yang